{"title":"[Progress in the application of dupilumab in pediatric dermatoses].","authors":"S Y Yang, J Sun, S Wang, B Zhang","doi":"10.3760/cma.j.cn112150-20250128-00080","DOIUrl":null,"url":null,"abstract":"<p><p>Dupilumab is a fully human monoclonal antibody that exerts its effects by targeting and binding to the interleukin (IL)-4 receptor alpha subunit, thereby blocking IL-4/13 signaling and downregulating Type 2 inflammation. It has been approved in China for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 6 months and older, as well as prurigo nodularis (PN) and bullous pemphigoid in adults. Given its approval age and safety profile, the application of Dupilumab in children has unique advantages, and it has been widely used in the treatment of various Type 2 inflammation-associated and other pediatric dermatologic conditions.Early and proactive management of type 2 inflammatory dermatoses may have preventive and therapeutic implications for modulating the atopic march and type 2 inflammatory comorbidities. This article reviews and summarizes the recent applications of dupilumab in pediatric dermatological diseases.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":"59 9","pages":"1575-1583"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华预防医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112150-20250128-00080","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Dupilumab is a fully human monoclonal antibody that exerts its effects by targeting and binding to the interleukin (IL)-4 receptor alpha subunit, thereby blocking IL-4/13 signaling and downregulating Type 2 inflammation. It has been approved in China for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 6 months and older, as well as prurigo nodularis (PN) and bullous pemphigoid in adults. Given its approval age and safety profile, the application of Dupilumab in children has unique advantages, and it has been widely used in the treatment of various Type 2 inflammation-associated and other pediatric dermatologic conditions.Early and proactive management of type 2 inflammatory dermatoses may have preventive and therapeutic implications for modulating the atopic march and type 2 inflammatory comorbidities. This article reviews and summarizes the recent applications of dupilumab in pediatric dermatological diseases.
期刊介绍：
Chinese Journal of Preventive Medicine (CJPM), the successor to Chinese Health Journal , was initiated on October 1, 1953. In 1960, it was amalgamated with the Chinese Medical Journal and the Journal of Medical History and Health Care , and thereafter, was renamed as People’s Care . On November 25, 1978, the publication was denominated as Chinese Journal of Preventive Medicine . The contents of CJPM deal with a wide range of disciplines and technologies including epidemiology, environmental health, nutrition and food hygiene, occupational health, hygiene for children and adolescents, radiological health, toxicology, biostatistics, social medicine, pathogenic and epidemiological research in malignant tumor, surveillance and immunization.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
